Several long-acting GLP-1 receptor agonists have been clinically approved for the treatment of type 2 diabetes [9] and more recently also for the treatment of obesity (Saxenda® and Wegovy®). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.